Chemotherapy among patients with triple negative breast cancer based on integrated mRNA-lncRNA signature
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated
mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial
نظر دهید